SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision ...

Kura Sushi USA, Inc. operates technology-enabled Japanese restaurants in the United States. The company was formerly known as Kula Sushi USA, Inc. and changed its name to Kura Sushi USA, Inc.

NASDAQ KURA opened at $8.65 on Thursday. The company’s fifty day moving average price is $8.79 and its two-hundred day moving average price is $15.11. The company has a debt-to-equity ratio of 0 ...

Kura Oncology (NASDAQ:KURA) stock slid 7% in post-market trading after the company issued an update on its drug ziftomenib. Kura (NASDAQ:KURA) reported positive Phase 2 data from a registration ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Kura Oncology (KURA – Research Report) today. The company’s shares closed yesterday at $9.05. Leverage the power of TipRanks' Smart ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kura Oncology (KURA – Research Report) and Steris (STE – Research Report) with bullish sentiments.

Kura Oncology, Inc. has a 12-month low of $6.98 and a 12-month high of $24.17. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura plans to submit an NDA for ziftomenib in Q2 2025 and initiate two Phase 3 trials in newly diagnosed AML patients in H2 2025. Get access to your new suite of high-powered trading tools ...

SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines ...